Intelligent Bio Solutions has signed a non-exclusive strategic alliance with Vlepis to develop wearable screening tools and speed its move into consumer health monitoring.
Announced on 18 December 2025, the alliance pools research and development, distribution and regulatory expertise to support a faster international rollout.
Non-invasive means tests that do not puncture the skin. Wearable patches are small, skin-applied sensors that capture readings such as temperature for remote monitoring.
Sydney-based Vlepis’ sensing and wearable-patch technologies will sit alongside INBS’ portfolio, which includes the Intelligent Fingerprinting Drug Testing Solution and the newly distributed SMARTOX SmarTest Patch. Fingerprint sweat analysis screens for recent drug use by analysing trace amounts of sweat collected from a fingertip.
Demand for non-invasive tools is rising as the wearables market grows: the global wearable medical devices market was valued at about US$42.7bn in 2024 and is projected to reach roughly US$168.3bn by 2030, growing at more than 25 per cent annually. The broader consumer healthcare sector is estimated at about US$383.7bn, rising to around US$548.7bn by 2030.
Planned work includes co-development, expanded distribution and evaluation of Vlepis’ software that links devices such as a remote monitoring thermometer to cloud platforms and mobile applications. INBS says aligning its Intelligent Fingerprinting System and SmarTest Patch with Vlepis’ wearables could open business-to-business-to-consumer and direct-to-consumer channels.
Harry Simeonidis, president and chief executive at Intelligent Bio Solutions, said: “This partnership with Vlepis strengthens our ability to develop innovative testing and monitoring technologies for new sectors. By combining our non-invasive technologies and commercial expertise with Vlepis’ pioneering wearable solutions, we can accelerate entry into the consumer health monitoring sector – a market with strong international demand and long-term revenue potential.”
Bill Dimopoulos, chief executive and co-founder at Vlepis, said: “Vlepis is delighted to be partnering with Intelligent Bio Solutions, a key innovator in screening technologies. We continue to see substantial value in working with leading med-tech companies to expand our positive impact in health and wellbeing. INBS’ commercial strength and track record give us the ability to scale faster, while our wearable technologies broaden the scope of intelligent health monitoring. This collaboration will allow us to quickly harness our respective strengths to unlock commercial benefits and disrupt key sectors ripe for transformational change as they digitalise across a range of use cases.”
Both companies plan to leverage distributor relationships and regulatory expertise to speed commercialisation in key markets, building on INBS’ presence in more than 24 countries.
